Benjamin Palleiko Sells 7,294 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

Key Points

• CEO Benjamin Palleiko sold 7,294 shares of KalVista Pharmaceuticals at an average price of $15.84, reducing his ownership by 1.81% to approximately 395,189 shares.
• The company reported a significant earnings miss for the previous quarter, with an EPS of (3.69), failing to meet analysts' expectations of (0.83).
• Analysts have increased their price targets for KalVista Pharmaceuticals, with several firms rating the stock as a "buy" and a consensus price target of $26.29.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin Palleiko sold 7,294 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $15.84, for a total transaction of $115,536.96. Following the completion of the sale, the chief executive officer owned 395,189 shares of the company's stock, valued at approximately $6,259,793.76. The trade was a 1.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

KalVista Pharmaceuticals Stock Performance

Shares of KalVista Pharmaceuticals stock traded down $0.35 during midday trading on Tuesday, reaching $15.61. 1,086,862 shares of the company's stock traded hands, compared to its average volume of 751,757. The company has a market cap of $785.81 million, a price-to-earnings ratio of -4.23 and a beta of -0.10. The company's 50 day simple moving average is $13.97 and its 200 day simple moving average is $12.72. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $16.33.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same quarter last year, the company posted ($1.07) EPS. As a group, equities research analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on KALV. JMP Securities raised their price target on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a "market outperform" rating in a report on Tuesday, July 8th. HC Wainwright raised their price target on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. Finally, Leerink Partners raised their price target on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a report on Monday, July 7th. One analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $26.29.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KALV. Earned Wealth Advisors LLC acquired a new position in KalVista Pharmaceuticals in the 1st quarter valued at $44,000. BNP Paribas Financial Markets grew its position in KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company's stock worth $46,000 after purchasing an additional 1,292 shares during the last quarter. GAMMA Investing LLC grew its position in KalVista Pharmaceuticals by 567.3% in the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock worth $51,000 after purchasing an additional 3,767 shares during the last quarter. CWM LLC grew its position in KalVista Pharmaceuticals by 12,636.1% in the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company's stock worth $53,000 after purchasing an additional 4,549 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in KalVista Pharmaceuticals by 666.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after purchasing an additional 5,502 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.